Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
about
sameAs
GLP-1-based strategies: a physiological analysis of differential mode of actionSafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusNutritional modulation of endogenous glucagon-like peptide-1 secretion: a reviewInhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberineThe TRPA1 agonist, methyl syringate suppresses food intake and gastric emptying.Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial.Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.Emerging treatment options for type 2 diabetesRelease of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-ε pathway and modulated by endogenous H2S.Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.Impact of gastric emptying to the glycemic and insulinemic responses to a 75-g oral glucose load in older subjects with normal and impaired glucose toleranceGIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetesDesign, Synthesis, and Pharmacological Evaluation of Fused β-Homophenylalanine Derivatives as Potent DPP-4 Inhibitors.Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.Dipeptidyl peptidase 4 concentration influenced by serum insulin levels rather than arterial stiffness index in type 2 diabeticsA pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markersNovel Agents for the Treatment of Type 2 Diabetes.Diabetes-related alterations in the enteric nervous system and its microenvironment.Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and AdipocytesA meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure.Cardiovascular biology of the incretin system.Achieving "PeaK-A" insulin secretionIncreased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplicationUnmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents.A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.New directions for protease inhibitors directed drug discovery.Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Endobarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism.Incretin effects on β-cell function, replication, and mass: the human perspective.A Short-activating RNA Oligonucleotide Targeting the Islet β-cell Transcriptional Factor MafA in CD34(+) Cells.Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.Effects of GLP-1 and incretin-based therapies on gastrointestinal motor functionGlucagon-like peptide-1 potentiates glucose-stimulated insulin secretion via the transient receptor potential melastatin 2 channel.Microbial Regulation of Glucose Metabolism and Insulin Resistance.Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidase-4 inhibitors.GLP-I secretion in healthy and diabetic Wistar rats in response to aqueous extract of Momordica charantia.Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution
P2860
Q26997149-BFFF4C8A-C9FB-4534-A893-43F5903CF92CQ27027877-42C01A3E-ABCA-4F52-8C85-78B219DF7B63Q28070256-1F129CF0-CDE6-418A-9CD9-C1E440A28CECQ28253310-400164F7-EF3A-4447-9D4E-CFFBEBF1ECEFQ31131497-66011031-5777-4B5E-A06A-72D743929286Q33585850-986ED734-540E-4017-8BB5-CA05D99012F7Q34026346-AA137631-FDC1-4FEE-98F9-638E26CD5F68Q34068749-2C620FF8-E988-434A-8127-081E0FD89F03Q34381281-1D7A655C-FE7E-461C-BDD1-E1FFD4352518Q34441486-0390FF7E-1B56-46C3-B1A3-9F16A0F8FE04Q34530205-A65D5AE4-A218-4819-8C66-FC0E1DFDB7FFQ34631907-6343175E-9D95-4638-B890-BC150F750DC6Q34718860-EA647F6D-B0FA-4654-874C-90322A10DF47Q35615176-7BCA3975-BD32-4ED3-922C-DFBB1561959CQ35772029-F1984C42-85CF-4375-9937-DBD6C9FCF7FFQ35791546-1A5CB407-CD49-4DAD-89C7-FFE6E32D9B20Q35838203-7DCDC8F8-6D1C-461D-BC8F-1625674255BCQ35910421-F4719533-79DE-406A-9DE5-A88160372AAFQ35988135-3D2B3E84-B7DD-439B-AD88-B2D15C33A891Q36033466-DD87D986-ABE4-4E38-BE73-85B202961850Q36090588-27A1D586-E44D-4832-8C11-9B0869A13629Q36484283-D5089E5A-CB18-428B-9E9A-8D574121F823Q36796114-4F0B0563-11CC-4B8F-A45D-2C359AF5E09EQ37072663-54B72D52-C896-4C4D-9931-559D84AC8EABQ37161925-A366BEB8-D0D3-4963-AA9A-B32E58EFBEB5Q37568754-64B6035F-BB2D-411A-BD16-6A89BE6A29D2Q38638651-682E0E50-B923-4397-A216-3039EDF82D11Q39047697-FA639BD0-1919-4782-BD40-1ABF4F9CA2CAQ39549540-AAB83F7D-6C48-4151-A6DD-D03BF9F51FE0Q39988564-837D44C4-3291-4C44-A975-F14D2FCD00F3Q41459994-AAB1712B-6139-44C4-B094-7CFDA61E66F9Q42518451-167B8256-0E21-44F4-AF52-94289706501DQ42775479-B6A30987-FD46-42DD-BED9-378EDA9E722CQ47100431-3B0EE075-6953-4758-B54A-5AD4FD92C3B3Q47235131-D44E4B1B-9CC1-44AD-A79A-3E603DB4A692Q53543771-76E34238-EEDE-4AAA-A94C-D47DE11CCE07Q55260061-9C29A1C8-5CAD-4FF5-87DF-4ADEE4F0F349Q58167548-3046EFCA-234A-499E-B62B-AA9F0A854C25Q58168549-FA4E57E3-947A-4607-A468-544D086F2E80
P2860
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@ast
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@en
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@nl
type
label
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@ast
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@en
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@nl
prefLabel
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@ast
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@en
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@nl
P356
P1476
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
@en
P2093
M B Toft-Nielsen
P304
P356
10.1210/JCEM.86.8.7743
P407
P577
2001-08-01T00:00:00Z